eClinical Technology News

Wednesday, December 26, 2007 06:54 AM
  • New York, N.Y.-based Medidata Solutions electronic data capture (EDC) won an agreement with Boston, Mass.-based CRO Parexel through the Medidata’s non-exclusive service provider model, ASPire to win. Medidata stated the CRO was attracted to Rave’s broad user acceptance, ease of deployment and real-time access to clinical data. Medidata Solutions also landed a contract with Dublin-based Elan Pharmaceuticals for the technology company’s Medidata Rave solution. Medidata stated that much of Elan’s data management operations is outsourced so it needed a product that could be easily adopted by any CRO regardless of past experience with the technology. Elan will use the solution for mid-to-late stage trials in North America.
  • Cambridge, Mass.-based Akaza Research launched OpenClinica 2.2, a new version of the company’s open source clinical trial software. The updated version offers enhancements such as improved case report forms (CRFs), international language capability, full study audit reports and improved support for multi-site trials.
  • Cleveland, OH-based eClinical company Datatrak has signed a five-year contract with Japanese telecommunications group NTT Data Corp. The enterprise-wide subscription license agreement that calls for NTT Data to standardized its systems on Datatrak platform, allowing NTT Data new Life Science group. The deal is worth $2.4 million with $2.1 million in upfront cash. Any optional services for the platform would be contracted separately. The agreement also gives NTT Data the ability to sublicense the eClinical platform to Japanese contract research organizations (CROs).
  • Ft. Lauderdale, Fla-based OmniComm Systems has partnered with the City of Hope, a renowned research and treatment center for life-threatening diseases have entered into a new collaboration. The partnership is an effort to standardize the center’s case report forms and reporting tools to be aligned with the National Cancer Institute (NCI) requirements. City of Hope uses OmniComm’s EDC system TrialMaster.
Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs